CCS adapting to COVID-19 realities to support Canadians during and after the pandemic
Stay informed and inspired!
Subscribe to our monthly e-newsletter×
A new study has shown that a combination of two immunotherapy drugs can shrink brain tumours in patients with melanoma whose cancer had spread from their skin to the brain. The drugs, which are called checkpoint inhibitors, work by activating the immune system to attack brain cancer cells. Among cancers, melanoma is one of the most likely ones to spread to the brain. In patients whose cancer has spread, fewer than 20% will survive 1 year with standard treatments. Among the patients in the study who were given the two immunotherapy drugs, 82% survived more than 1 year after their cancer spread to the brain. Read more in an article from the New York Times.